The most prominent male birth control trial was stopped in 2016 because an independent safety review panel determined the injectable hormonal contraceptive caused too many side effects, particularly severe mood-related problems. But that single halted study is only part of the story. The deeper answer involves a combination of safety concerns, regulatory math, and a pharmaceutical industry that walked away from the entire field.
What Happened in the 2016 Trial
The study, coordinated by the World Health Organization, tested hormonal injections designed to temporarily suppress sperm production in men. It enrolled hundreds of participants across multiple countries, and the contraceptive was actually working well at preventing pregnancy. But two independent monitoring committees noticed a pattern: men were dropping out at concerning rates because of side effects.
The most common problem was acne, sometimes severe. Some participants developed significant mood swings. At the more serious end, one man developed severe depression and another attempted suicide. The committees decided the risk-benefit balance wasn’t acceptable and stopped the trial before it was complete.
What made this controversial was that 4.7 percent of men experienced mood swings and 2.8 percent experienced depression. Other reported side effects included increased sex drive, injection site pain, and muscle pain. Critics pointed out that women’s hormonal birth control causes similar side effects, and yet those products remain on the market. That comparison, while understandable, misses a key regulatory distinction.
The Risk-Benefit Problem
Drug regulators evaluate side effects against what the drug prevents. Female contraceptives are weighed against the real medical risks of pregnancy: preeclampsia, hemorrhage, gestational diabetes, and in some parts of the world, death. Pregnancy is a significant health event, so regulators accept a higher threshold of side effects in drugs that prevent it.
Male contraceptives face a fundamentally different calculation. The person taking the drug isn’t the one who faces the health risks of pregnancy. A healthy man with no medical condition is being asked to take a drug that introduces new risks to his body, and the direct physical benefit (avoiding pregnancy) accrues to someone else. This makes regulators far less tolerant of serious side effects. Severe depression and suicidal behavior in an otherwise healthy population is a harder sell through any approval process, even if the same side effects exist in female contraceptives approved decades ago under different standards.
This isn’t necessarily fair, but it is the regulatory reality that every male contraceptive candidate has to navigate.
Why Pharmaceutical Companies Left
The 2016 trial wasn’t the first setback. By the mid-2000s, major pharmaceutical companies had already abandoned contraceptive development programs altogether. The reasons were largely financial.
Developing a male contraceptive involves what researchers call multiple “valleys of death,” stages where a promising drug faces enormous scientific and financial obstacles before it can reach the market. The biology is harder than it sounds: effective contraception requires suppressing sperm concentration to roughly 1 million per milliliter or below, sustained over time, and then reliably reversing that suppression when the man stops treatment. A drug has to do this without disrupting testosterone levels enough to cause other problems.
On top of the science, the regulatory path is uncertain, the clinical trials are expensive and lengthy, and the market is unproven. Female contraceptives already exist and are widely used, so companies question whether enough men would switch to justify the investment. These combined developmental, regulatory, and financial risks made the pharmaceutical industry largely unwilling to keep funding the work. The field has since depended almost entirely on academic researchers and nonprofit organizations operating with far smaller budgets.
What’s Being Developed Now
Despite industry withdrawal, several approaches are still moving through clinical trials. The most advanced hormonal option is a daily gel containing a combination of two hormones that a man applies to his arms and shoulders. A phase 2b trial enrolled 420 men across multiple sites, with a 52-week period testing whether the gel could suppress sperm production effectively. That trial completed in September 2024, though results haven’t been published yet. The gel approach avoids injections, which researchers hope will reduce some of the mood-related side effects seen with the 2016 injectable formulation.
On the non-hormonal side, a drug called YCT-529 represents something genuinely new. It works by blocking a receptor in the testes that depends on a vitamin A metabolite essential for sperm development. When that receptor is blocked, sperm production drops without touching the hormonal system at all. A phase 1a trial in 16 healthy men found it was well tolerated, with no significant safety signals for mood, sex drive, or heart function. A longer trial is now underway, giving men the drug for 28 and 90 days to measure actual changes in sperm counts.
There’s also a physical approach. A hydrogel called ADAM is designed to be injected into the vas deferens, the tube that carries sperm, where it acts as a reversible plug. It’s essentially a non-permanent vasectomy: sperm can’t get through, but the gel can theoretically be dissolved later to restore fertility. A first-in-human trial is active, with results expected around early 2026.
Whether Men Would Actually Use It
One of the pharmaceutical industry’s long-standing doubts has been whether men would take a contraceptive even if one existed. Survey data suggests the answer is yes. In a study of over 2,000 men in the United States, 75 percent said they would be willing to use a new form of male contraception. Willingness was higher among men with more gender-equitable attitudes and among those who had experienced an unintended pregnancy that ended in abortion, who were roughly twice as likely to express interest.
The gap between that expressed willingness and an actual product on pharmacy shelves remains wide. But the demand side of the equation looks less like a barrier and more like a market waiting for something to buy.